InvestorsHub Logo
Followers 72
Posts 6896
Boards Moderated 0
Alias Born 12/07/2011

Re: None

Tuesday, 07/11/2017 7:15:34 AM

Tuesday, July 11, 2017 7:15:34 AM

Post# of 403096
B-UP Interim Data Here:

http://www.ipharminc.com/press-release/2017/3/19/cellceutix-releases-favorable-topline-findings-as-part-of-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-the-treatment-of-inflammatory-bowel-disease

Patient Quality of Life (as assessed by the Short Inflammatory Bowel Disease Questionnaire, SIBDQ)—notable improvements in all 12 patients; 50 percent of patients in Cohort A (3 of 6) and 80 percent of patients in Cohort B (5 of 6) reported significant improvements of 15 points to more than 50 points higher on the 70-point SIBDQ scale.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News